CytoMed Therapeutics Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net loss was SGD 0.995287 million compared to SGD 1.03 million a year ago. Basic loss per share from continuing operations was SGD 0.1523 compared to SGD 0.1523 a year ago.

Diluted loss per share from continuing operations was SGD 0.1523 compared to SGD 0.1523 a year ago.